AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638.
作者信息
Zhou Wen, Limonta Patrizia
机构信息
Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , Miami, FL , USA.
Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano , Milan , Italy.
出版信息
Front Oncol. 2014 Jun 23;4:162. doi: 10.3389/fonc.2014.00162. eCollection 2014.
Abstract
摘要
相似文献
1
AKR1C3 Inhibition Therapy in Castration-Resistant Prostate Cancer and Breast Cancer: Lessons from Responses to SN33638.去势抵抗性前列腺癌和乳腺癌中的AKR1C3抑制疗法：从对SN33638的反应中获得的经验教训。
Front Oncol. 2014 Jun 23;4:162. doi: 10.3389/fonc.2014.00162. eCollection 2014.
2
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.SN33638，一种 AKR1C3 抑制剂，对去势抵抗性前列腺癌和 ER 阳性乳腺癌中睾酮和 17β-雌二醇产生和功能的影响。
Front Oncol. 2014 Jun 18;4:159. doi: 10.3389/fonc.2014.00159. eCollection 2014.
3
Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.醛酮还原酶 1C3（AKR1C3）在 LNCaP 细胞中的过表达将雄激素代谢转向睾酮，导致对 5α-还原酶抑制剂非那雄胺的耐药性。
J Steroid Biochem Mol Biol. 2012 May;130(1-2):7-15. doi: 10.1016/j.jsbmb.2011.12.012. Epub 2012 Jan 12.
4
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.内源性雄激素和 AKR1C3 的激活可导致前列腺癌对恩杂鲁胺产生耐药性。
Cancer Res. 2015 Apr 1;75(7):1413-22. doi: 10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3.
5
Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo.介孔硅纳米颗粒联合 AKR1C3 siRNA 通过抑制雄激素合成抑制体外和体内去势抵抗性前列腺癌的生长。
Biochem Biophys Res Commun. 2021 Feb 12;540:83-89. doi: 10.1016/j.bbrc.2020.11.074. Epub 2021 Jan 12.
6
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.醛酮还原酶家族 1 成员 C3（AKR1C3）是去势抵抗性前列腺癌的生物标志物和治疗靶点。
Mol Med. 2013 Jan 22;18(1):1449-55. doi: 10.2119/molmed.2012.00296.
7
Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).5型17β-羟基类固醇脱氢酶（AKR1C3）的结构-功能方面及抑制剂设计
Mol Cell Endocrinol. 2001 Jan 22;171(1-2):137-49. doi: 10.1016/s0303-7207(00)00426-3.
8
Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.人醛糖酮还原酶AKR1C3（2型3α-羟基类固醇脱氢酶/5型17β-羟基类固醇脱氢酶）单克隆抗体的特性；乳腺和前列腺中的免疫组织化学检测
Steroids. 2004 Dec;69(13-14):795-801. doi: 10.1016/j.steroids.2004.09.014.
9
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).ASP9521的体外和体内特性：一种新型、选择性、口服生物可利用的5型17β-羟基类固醇脱氢酶（17βHSD5；AKR1C3）抑制剂。
Invest New Drugs. 2014 Oct;32(5):860-70. doi: 10.1007/s10637-014-0130-5. Epub 2014 Jul 1.
10
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.AKR1C3 在转移性去势抵抗性前列腺癌时的原发肿瘤再次活检中的表达与阿比特龙作为一线治疗的疗效差密切相关。
Prostate. 2019 Sep;79(13):1553-1562. doi: 10.1002/pros.23875. Epub 2019 Jul 11.
引用本文的文献
1
Per- and Polyfluoroalkyl Substances (PFAS) Enhance Cholesterol Accumulation and Dysregulate Inflammatory Responses in Macrophages.全氟和多氟烷基物质（PFAS）增强巨噬细胞中的胆固醇积累并失调炎症反应。
Cardiovasc Toxicol. 2025 Jul 29. doi: 10.1007/s12012-025-10048-w.
2
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3.作为醛酮还原酶1C3抑制剂的吲哚美辛生物电子等排体
ACS Med Chem Lett. 2019 Jan 28;10(4):437-443. doi: 10.1021/acsmedchemlett.8b00484. eCollection 2019 Apr 11.
3
Identification of Aberrant Chromosomal Regions in Human Breast Cancer Using Gene Expression Data and Related Gene Information.利用基因表达数据和相关基因信息鉴定人类乳腺癌中的异常染色体区域
Med Sci Monit. 2015 Aug 29;21:2557-66. doi: 10.12659/MSM.894887.
本文引用的文献
1
The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.SN33638，一种 AKR1C3 抑制剂，对去势抵抗性前列腺癌和 ER 阳性乳腺癌中睾酮和 17β-雌二醇产生和功能的影响。
Front Oncol. 2014 Jun 18;4:159. doi: 10.3389/fonc.2014.00159. eCollection 2014.
2
Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy.雌激素受体激活与蛋白水解之间的联系：与激素调节的癌症治疗的相关性。
Nat Rev Cancer. 2014 Jan;14(1):26-38. doi: 10.1038/nrc3622.
3
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.1-(4-(哌啶-1-磺酰基)苯基)吡咯烷-2-酮类作为新型非羧酸酯抑制剂的合成及构效关系研究，用于醛酮还原酶 AKR1C3。
Eur J Med Chem. 2013 Apr;62:738-44. doi: 10.1016/j.ejmech.2013.01.047. Epub 2013 Feb 9.
4
In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology.人乳腺癌中雌激素的原位生成及其调控：从内分泌学到细胞内分化学。
Pathol Int. 2009 Nov;59(11):777-89. doi: 10.1111/j.1440-1827.2009.02444.x.
5
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.转移性前列腺癌中瘤内雄激素的维持：去势抵抗性肿瘤生长的一种机制。
Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249.
6
The development of androgen-independent prostate cancer.雄激素非依赖性前列腺癌的发展。
Nat Rev Cancer. 2001 Oct;1(1):34-45. doi: 10.1038/35094009.
Zotero 插件